In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Harry Bowen, Economic Research Partner at Vital Transformation, about Most-Favored-Nation (MFN) drug pricing and the lessons they draw from Europe's experience with price controls. They discuss how pricing rules, revenue uncertainty, and regulatory choices influence market access and the geography of pharmaceutical innovation.
Key Topics:
Resources Discussed:
Opinions expressed are those of the speakers. Discussion recorded on 9/19/26.
#VitalHealthPodcast #MFN #DrugPricing

Michael Penn: What The IRA Means For Oncology Innovation
27:47

MSD Early Bird Podcast: Changing Demographics and the Case for Renewed Investment in Health
25:07

Bill Smith: How 340B Became A Hospital Profit Center
23:18